This is an aggregated industry headline. Read the full story at FierceBiotech →
Apnimed's IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
By FierceBiotech
· Jul 31, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Shionogi's "Got the Call, Make the Call" campaign for COVID antiviral Xocova kicks off with a TV ad depicting …
The WeekBriefing
FDA’s July 30 notice sets FY 2027 PDUFA fees below FY 2026 levels for clinical-data applications, non-clinical…
The WeekPharmaceutical Technology ↗
US efforts to scrutinise overseas drug manufacturing could expose Europe's role in supplying FDA-approved inno…